**Sanofi India Q4 Results 2025**
On February 27, 2025, Sanofi India announced its Q4 results, revealing a 9.74% increase in topline revenue compared to the previous year, reaching ₹514.9 crore. However, the company experienced a significant profit decline of 33.7%, resulting in a net income of ₹91.3 crore.
When compared to the previous quarter, revenue saw a slight decrease of 1.74%, while profit increased by 11.07%, indicating variability in performance amid changing market conditions. Notably, Selling, General, and Administrative expenses decreased by 5.11% quarter-on-quarter and by 25.79% year-on-year, which may positively impact future profitability as the company optimizes its operational costs.
Operating income fell by 1.81% from the previous quarter but rose by 20.38% year-on-year, demonstrating resilience in operational performance despite the profit drop. The Earnings Per Share (EPS) for Q4 was reported at ₹37.04, reflecting a year-on-year increase of 22.41%, suggesting effective management in enhancing shareholder value despite the overall profit decline.
In the past week, Sanofi India shares have returned -4.68%, with a -26.35% return over the last six months and a -18.55% year-to-date return, indicating a challenging market environment for investors. As of February 28, 2025, the company has a market capitalization of ₹11,756.81 crore, with a 52-week high of ₹7,600 and a low of ₹4,694.05, highlighting stock price volatility.
Among the two analysts covering Sanofi India, one has issued a Buy rating while the other has assigned a Strong Buy rating, reflecting mixed market sentiment regarding the company’s future performance. The consensus recommendation as of February 28, 2025, remains a Strong Buy, indicating analysts’ confidence in the long-term growth prospects of Sanofi India despite the recent quarterly results.
**Sanofi India Financials**
| Period | Q4 (FY24) | Q3 (FY24) | Q-o-Q Growth | Q4 (FY23) | Y-o-Y Growth |
|———————-|———–|———–|————–|———–|————–|
| Total Revenue | 514.9 | 524 | -1.74% | 469.2 | +9.74% |
| Selling/General/Admin Expenses Total | 53.8 | 56.7 | -5.11% | 72.5 | -25.79% |
| Depreciation/Amortization | 9.6 | – | +6.67% | 9.3 | +3.23% |
| Total Operating Expense | 406.2 | 413.3 | -1.72% | 378.9 | +7.21% |
| Operating Income | 108.7 | 110.7 | -1.81% | 90.3 | +20.38% |
| Net Income Before Taxes | 122.2 | 112.6 | +8.53% | 99.3 | +23.06% |
| Net Income | 91.3 | 82.2 | +11.07% | 137.7 | -33.7% |
| Diluted Normalized EPS | 37.04 | 35.69 | +3.78% | 30.26 | +22.41% |
